Mercaptopurine
- Generic Name
- Mercaptopurine
- Brand Names
- Purixan, Xaluprine (previously Mercaptopurine Nova Laboratories)
- Drug Type
- Small Molecule
- Chemical Formula
- C5H4N4S
- CAS Number
- 50-44-2
- Unique Ingredient Identifier
- PKK6MUZ20G
- Background
An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia.
- Indication
For remission induction and maintenance therapy of acute lymphatic leukemia.
- Associated Conditions
- Acute Lymphoblastic Leukaemias (ALL), Acute Promyelocytic Leukemia, Autoimmune Hepatitis, Crohn's Disease (CD), Lymphoblastic Lymphoma, Ulcerative Colitis
Study of Carfilzomib in Combination With Induction Chemotherapy in Children With Relapsed or Refractory Acute Lymphoblastic Leukemia
- Conditions
- Acute Lymphoblastic Leukemia (ALL)
- Interventions
- Drug: Intrathecal Triple Therapy (Intrathecal Cytarabine, Hydrocortisone, and Methotrexate)
- First Posted Date
- 2014-12-01
- Last Posted Date
- 2024-07-16
- Lead Sponsor
- Amgen
- Target Recruit Count
- 130
- Registration Number
- NCT02303821
- Locations
- 🇺🇸
Childrens Healthcare of Atlanta, Egleston, Atlanta, Georgia, United States
🇺🇸West Virginia University Medicine Childrens, Morgantown, West Virginia, United States
🇹🇷Medical Park Bahcelievler Hastanesi, Istanbul, Turkey
Phase I Study of MLN 9708 in Addition to Chemotherapy for the Treatment of Acute Lymphoblastic Leukemia in Older Adults
- Conditions
- Acute Lymphoblastic LeukemiaLymphoblastic LymphomaB-cell Adult Acute Lymphoblastic LeukemiaT-cell Adult Acute Lymphoblastic Leukemia
- Interventions
- First Posted Date
- 2014-08-29
- Last Posted Date
- 2019-11-26
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 19
- Registration Number
- NCT02228772
- Locations
- 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
LCH-IV, International Collaborative Treatment Protocol for Children and Adolescents With Langerhans Cell Histiocytosis
- Conditions
- Langerhans Cell Histiocytosis
- Interventions
- Procedure: hematopoietic stem cell transplantation (RIC-HSCT)Biological: Intravenous immunoglobulin
- First Posted Date
- 2014-07-31
- Last Posted Date
- 2023-03-23
- Lead Sponsor
- North American Consortium for Histiocytosis
- Target Recruit Count
- 1400
- Registration Number
- NCT02205762
- Locations
- 🇺🇸
Children's Medical Center Dallas, UT Southwestern, Dallas, Texas, United States
🇺🇸Children's Hospital of Los Angeles, Los Angeles, California, United States
🇺🇸Hackensack University Medical Center, Hackensack, New Jersey, United States
A Study for Improving the Outcome of Childhood Acute Promyeloid Leukemia
- Conditions
- Childhood Acute Promyelocytic Leukemia
- Interventions
- Drug: ATODrug: RIFOther: intrathecal injection
- First Posted Date
- 2014-07-25
- Last Posted Date
- 2022-05-10
- Lead Sponsor
- South China Children's Leukemia Group
- Target Recruit Count
- 176
- Registration Number
- NCT02200978
- Locations
- 🇨🇳
The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, Guangdong, China
A proSpective Randomized Controlled Trial comParing infliximAb-antimetabolites Combination Therapy to Anti-metabolites monotheRapy and Infliximab monothErapy in Crohn's Disease Patients in Sustained Steroid-free Remission on Combination Therapy
- Conditions
- Crohn's Disease
- Interventions
- First Posted Date
- 2014-06-27
- Last Posted Date
- 2022-08-03
- Lead Sponsor
- Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives
- Target Recruit Count
- 211
- Registration Number
- NCT02177071
- Locations
- 🇦🇺
St Vincent Hospital, Melbourne, Australia
🇫🇷Chu Clermont-Ferrand, Clermont-ferrand, Auvergne Rhone Alpes, France
🇫🇷CHU LYON, Pierre Benite, Auvergne Rhone Alpes, France
Blinatumomab and Combination Chemotherapy or Dasatinib, Prednisone, and Blinatumomab in Treating Older Patients With Acute Lymphoblastic Leukemia
- Conditions
- Acute Lymphoblastic LeukemiaB Acute Lymphoblastic LeukemiaB Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1Recurrent Acute Lymphoblastic LeukemiaRefractory Acute Lymphoblastic Leukemia
- Interventions
- Procedure: Biopsy ProcedureProcedure: Biospecimen CollectionProcedure: Bone Marrow Aspiration and BiopsyProcedure: Computed TomographyProcedure: Echocardiography TestProcedure: Lumbar PunctureProcedure: Magnetic Resonance ImagingProcedure: X-Ray Imaging
- First Posted Date
- 2014-05-21
- Last Posted Date
- 2025-05-14
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 53
- Registration Number
- NCT02143414
- Locations
- 🇺🇸
University of Alabama at Birmingham Cancer Center, Birmingham, Alabama, United States
🇺🇸Banner University Medical Center - Tucson, Tucson, Arizona, United States
🇺🇸University of Arizona Cancer Center-North Campus, Tucson, Arizona, United States
Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma
- Conditions
- Adult T Acute Lymphoblastic LeukemiaAnn Arbor Stage II Adult Lymphoblastic LymphomaAnn Arbor Stage II Childhood Lymphoblastic LymphomaAnn Arbor Stage III Adult Lymphoblastic LymphomaAnn Arbor Stage III Childhood Lymphoblastic LymphomaAnn Arbor Stage IV Adult Lymphoblastic LymphomaAnn Arbor Stage IV Childhood Lymphoblastic LymphomaChildhood T Acute Lymphoblastic Leukemia
- Interventions
- Radiation: Radiation Therapy
- First Posted Date
- 2014-04-14
- Last Posted Date
- 2025-03-20
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 847
- Registration Number
- NCT02112916
- Locations
- 🇺🇸
Cleveland Clinic Foundation, Cleveland, Ohio, United States
🇺🇸Mercy Children's Hospital, Toledo, Ohio, United States
🇺🇸Children's Hospital of Alabama, Birmingham, Alabama, United States
Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic Leukemia
- Conditions
- Recurrent B Acute Lymphoblastic Leukemia
- Interventions
- Procedure: Allogeneic Hematopoietic Stem Cell TransplantationOther: Pharmacological StudyRadiation: Radiation Therapy
- First Posted Date
- 2014-04-02
- Last Posted Date
- 2025-03-20
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 669
- Registration Number
- NCT02101853
- Locations
- 🇺🇸
Legacy Emanuel Children's Hospital, Portland, Oregon, United States
🇺🇸Southern Illinois University School of Medicine, Springfield, Illinois, United States
🇺🇸Saint Jude Midwest Affiliate, Peoria, Illinois, United States
Pethema LAL-RI/2008: Treatment for Patients With Standard Risk Acute Lymphoblastic Leukemia
- Conditions
- Acute Lymphobkastic Leukemia
- Interventions
- Drug: CiclophosphamideDrug: MetotrexateDrug: HidrocortisoneDrug: Dexametasone
- First Posted Date
- 2014-01-15
- Last Posted Date
- 2020-03-05
- Lead Sponsor
- PETHEMA Foundation
- Target Recruit Count
- 107
- Registration Number
- NCT02036489
- Locations
- 🇪🇸
Hospital Germans Trias i Pujol, Barcelona, Spain
Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia
- Conditions
- Acute Lymphoblastic LeukemiaB Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative
- Interventions
- Procedure: Allogeneic Hematopoietic Stem Cell TransplantationProcedure: Biospecimen CollectionProcedure: Bone Marrow AspirationProcedure: Bone Marrow BiopsyProcedure: Lumbar PunctureProcedure: X-Ray Imaging
- First Posted Date
- 2013-12-06
- Last Posted Date
- 2025-05-11
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 488
- Registration Number
- NCT02003222
- Locations
- 🇵🇷
Doctors Cancer Center, Manati, Puerto Rico
🇵🇷San Juan Community Oncology Group, San Juan, Puerto Rico
🇵🇷Centro Comprensivo de Cancer de UPR, San Juan, Puerto Rico
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.